Acute Promyelocytic Leukemia (APL/AML M3)

Acute promyelocytic leukemia (APL, formerly FAB AML-M3) is a distinct molecular subtype of acute myeloid leukemia comprising approximately 5-15% of AML cases (10-30% of AML in Hispanic and Latino populations, lower in East Asian and African populations), characterized in 99% by the t(15;17)(q24;q21) chromosomal translocation generating the PML-RARA fusion oncoprotein. Rare variant translocations involving RARA partners include ZBTB16 (PLZF, t(11;17), ATRA-resistant), NPM1 (NPM, t(5;17), ATRA-sensitive), STAT5B (rare, ATRA-resistant), NUMA1 (rare), among others. The PML-RARA oncoprotein dominantly inhibits normal RARA function and PML nuclear body assembly, blocking myeloid differentiation at the promyelocyte stage and preventing apoptosis. ATRA and arsenic trioxide overcome this block by promoting PML-RARA degradation and restoring differentiation/apoptosis pathways.

Epidemiology: incidence approximately 0.1 per 100,000 per year (10-15% of AML), median age 40-50 years (younger than other AML subtypes), no male predominance, increased incidence in Hispanic/Latino populations (genetic susceptibility, possibly TET2/SF3B1 polymorphisms). Risk factors include prior chemotherapy with topoisomerase II inhibitors (anthracyclines, etoposide — therapy-related APL representing 5-10% of APL cases), genetic predisposition, no clear environmental factors. Clinical presentation: APL is a hematologic emergency due to characteristic life-threatening coagulopathy (disseminated intravascular coagulation, hyperfibrinolysis, hypofibrinogenemia) causing severe bleeding (intracranial hemorrhage 5-15% mortality before treatment era, mucocutaneous bleeding, gastrointestinal bleeding, hemoptysis), pancytopenia with leukopenia (hypogranular variant) or hyperleukocytosis (microgranular variant, M3v), bone marrow failure symptoms (fatigue, infection, bleeding), often less than 4 weeks symptom duration before diagnosis.

Diagnosis is a hematologic emergency requiring immediate suspicion based on coagulopathy and morphology, with rapid molecular confirmation. Bone marrow shows hypergranular abnormal promyelocytes (classical APL) with bundles of Auer rods (faggot cells, pathognomonic), or hypogranular/microgranular promyelocytes (M3v) with bilobed/butterfly nuclei. Immunophenotype: CD33+ CD13+ CD117+ MPO+ HLA-DR negative (classical, distinguishes from other AML), CD34 negative (classical) or positive (microgranular variant), CD56+ in subset (worse prognosis). Molecular confirmation: PML-RARA fusion by reverse transcription PCR (RT-PCR, gold standard for diagnosis and minimal residual disease monitoring), fluorescence in situ hybridization (FISH) for PML-RARA, conventional karyotyping for t(15;17). Treatment: APL is an oncologic emergency — initiate ATRA immediately on suspicion (before molecular confirmation) at 45 mg/m2/day to prevent catastrophic bleeding. Risk stratification (Sanz criteria): low-risk (WBC <10,000/uL, platelets >40,000/uL), intermediate-risk (WBC <10,000, platelets <40,000), high-risk (WBC >10,000). Standard-risk (low and intermediate) treatment: ATRA + arsenic trioxide (ATO) chemotherapy-free induction and consolidation (4 cycles consolidation) — superior to ATRA + chemotherapy in clinical trials with cure rates >90% (APL0406 study). High-risk treatment: ATRA + ATO + idarubicin or cytarabine for induction and consolidation. Maintenance ATRA ± methotrexate ± mercaptopurine for 1-2 years (less commonly used now). Differentiation syndrome (formerly retinoic acid syndrome) — life-threatening complication (10-25%) with fever, dyspnea, weight gain, pulmonary infiltrates, pleural/pericardial effusions, hypotension, renal failure — managed with dexamethasone (10 mg twice daily). Aggressive supportive care: platelet transfusion goal >30-50,000/uL, fibrinogen replacement (cryoprecipitate) >1.5 g/L, fresh frozen plasma for INR/PTT correction. Minimal residual disease monitoring by RT-PCR for PML-RARA every 3 months for 2 years post-treatment. Late relapses uncommon. Long-term outcomes excellent: 5-year overall survival >90% for standard-risk, 80-85% for high-risk.